Post-Transplant Thrombotic Microangiopathy in Kidney Transplant Recipients: Clinical, Genetic, and Therapeutic Outcomes from a Single-Center Cohort (TTS 2026) - Sep 17, 2026 - Abstract #P3.681; Pres time: Sep 21, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P3; "Rituximab was used in 5 patients, most commonly as a single 500 mg dose, with one patient receiving 500 mg ×2 doses and another 200 mg. Eculizumab (900 mg) was administered in one patient with persistent disease activity despite plasma exchange–based therapy, reflecting a high-risk complement-mediated phenotype and suboptimal response to conventional immunomodulation, following which clinical and graft functional recovery was achieved... Post-transplant TMA is strongly associated with underlying complement genetic abnormalities, particularly involving the CFHR1–CFHR3 axis. A phenotype-driven approach incorporating early biopsy confirmation, comprehensive genetic evaluation, and timely plasma exchange–based therapy with selective immunomodulation, with escalation to complement inhibition in refractory cases, enables effective disease control and sustained graft function even in biologically high-risk patients."
Clinical • Post-transplantation • Cardiovascular • Hematological Disorders • Immunology • Thrombosis • Transplantation • CFHR3
|
|
Nishtha Manuja1; Pranjal Kashiv1; Mohit Kurundwadkar1; Amol Bhawane2; Charulata Bawankule1,3; Akanshu Jain1; kapil sejpal1; Sunny Malde1; Amit Pasari1,3; Manish Balwani1,3
|